Vacunas SARS-CoV-2: evolución y escape

Autores:: Rivero-Herrera, Ricardo
González-Tous, Marco
Mattar, Salim

Tipo de recurso:: Article of journal

Fecha de publicación:: 2021

Institución:: Universidad de Córdoba

Repositorio:: Repositorio Institucional Unicórdoba

Idioma:: spa

id	UCORDOBA2_59c64ef641a7a88a0693d8c75258990a
oai_identifier_str	oai:repositorio.unicordoba.edu.co:ucordoba/6132
network_acronym_str	UCORDOBA2
network_name_str	Repositorio Institucional Unicórdoba
repository_id_str
dc.title.spa.fl_str_mv	Vacunas SARS-CoV-2: evolución y escape
dc.title.translated.eng.fl_str_mv	SARS-CoV-2 vaccines: evolution and escape
title	Vacunas SARS-CoV-2: evolución y escape
spellingShingle	Vacunas SARS-CoV-2: evolución y escape SARS-CoV-2 vaccines viral strains SARS-CoV-2 vacunas cepas virales
title_short	Vacunas SARS-CoV-2: evolución y escape
title_full	Vacunas SARS-CoV-2: evolución y escape
title_fullStr	Vacunas SARS-CoV-2: evolución y escape
title_full_unstemmed	Vacunas SARS-CoV-2: evolución y escape
title_sort	Vacunas SARS-CoV-2: evolución y escape
dc.creator.fl_str_mv	Rivero-Herrera, Ricardo González-Tous, Marco Mattar, Salim
dc.contributor.author.spa.fl_str_mv	Rivero-Herrera, Ricardo González-Tous, Marco Mattar, Salim
dc.subject.eng.fl_str_mv	SARS-CoV-2 vaccines viral strains
topic	SARS-CoV-2 vaccines viral strains SARS-CoV-2 vacunas cepas virales
dc.subject.spa.fl_str_mv	SARS-CoV-2 vacunas cepas virales
publishDate	2021
dc.date.accessioned.none.fl_str_mv	2021-05-02 00:00:00 2022-07-01T21:01:51Z
dc.date.available.none.fl_str_mv	2021-05-02 00:00:00 2022-07-01T21:01:51Z
dc.date.issued.none.fl_str_mv	2021-05-02
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_b239
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ARTEDIT
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	0122-0268
dc.identifier.uri.none.fl_str_mv	https://repositorio.unicordoba.edu.co/handle/ucordoba/6132
dc.identifier.doi.none.fl_str_mv	10.21897/rmvz.2372
dc.identifier.url.none.fl_str_mv	https://doi.org/10.21897/rmvz.2372
dc.identifier.eissn.none.fl_str_mv	1909-0544
identifier_str_mv	0122-0268 10.21897/rmvz.2372 1909-0544
url	https://repositorio.unicordoba.edu.co/handle/ucordoba/6132 https://doi.org/10.21897/rmvz.2372
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Worldometer. COVID-19 coronavirus pandemic. [Internet]. Worldometer; 2021. Available from: https://www.worldometers.info/coronavirus/ Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48):eabc8413. https://doi.org/10.1126/sciimmunol.abc8413 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389 NIH. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released. USA: National Institutes of Health (NIH); 2021. https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released AstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. Cambridge, UK, AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html Logunov DY, Dolzhikova I V., Shcheblyakov D V., Tukhvatulin AI, Zubkova O V., Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397(10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8 Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC - Supply Vaccines to Eliminate Human Diseases. Available from: http://www.sinovac.com/?optionid=754&auto_id=922 Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; https://doi.org/10.1038/s41591-021-01285-x Callaway E. The coronavirus is mutating - does it matter? Nature. 2020; 585:174-177. https://doi.org/10.1038/d41586-020-02544-6 Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMc2102179 Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021. https://doi.org/10.1038/s41586-021-03324-6 Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184:1-12. https://doi.org/10.1016/j.cell.2021.03.013 van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv. 2020; 11.17.20233726. https://doi.org/10.1101/2020.11.17.20233726 Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020; 9: e61312. https://doi.org/10.7554/eLife.61312
dc.relation.bitstream.none.fl_str_mv	https://revistamvz.unicordoba.edu.co/article/download/e2372/2982 https://revistamvz.unicordoba.edu.co/article/download/e2372/2983 https://revistamvz.unicordoba.edu.co/article/download/e2372/3484 https://revistamvz.unicordoba.edu.co/article/download/e2372/3486 https://revistamvz.unicordoba.edu.co/article/download/e2372/3485 https://revistamvz.unicordoba.edu.co/article/download/e2372/3487 https://revistamvz.unicordoba.edu.co/article/download/e2372/2984 https://revistamvz.unicordoba.edu.co/article/download/e2372/2985
dc.relation.citationedition.spa.fl_str_mv	Núm. 3 , Año 2021 : Revista MVZ Córdoba Volumen 26(3) Septiembre-Diciembre 2021
dc.relation.citationendpage.none.fl_str_mv	e2372
dc.relation.citationissue.spa.fl_str_mv	3
dc.relation.citationstartpage.none.fl_str_mv	e2372
dc.relation.citationvolume.spa.fl_str_mv	26
dc.relation.ispartofjournal.spa.fl_str_mv	Revista MVZ Córdoba
dc.rights.spa.fl_str_mv	Ricardo Rivero-Herrera, Marco González-Tous, Salim Mattar - 2021
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Ricardo Rivero-Herrera, Marco González-Tous, Salim Mattar - 2021 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf application/pdf application/zip application/zip application/xml application/xml audio/mpeg audio/mpeg
dc.publisher.spa.fl_str_mv	Universidad de Córdoba
dc.source.spa.fl_str_mv	https://revistamvz.unicordoba.edu.co/article/view/e2372
institution	Universidad de Córdoba
bitstream.url.fl_str_mv	https://repositorio.unicordoba.edu.co/bitstreams/ff733d9c-2bba-4fdc-8790-827a86e88ecc/download
bitstream.checksum.fl_str_mv	f68c58c90f22dc6b08eb02d4e297246f
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Universidad de Córdoba
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1839636145713971200
spelling	Rivero-Herrera, Ricardoec187b45-3d29-4eb3-9fbe-492b77890a96-1González-Tous, Marco4a3eda1a-4329-4c0b-86d5-024c8dd16b6c-1Mattar, Salim37b53d5c-2c63-4be9-baf1-962f2b90b32f-12021-05-02 00:00:002022-07-01T21:01:51Z2021-05-02 00:00:002022-07-01T21:01:51Z2021-05-020122-0268https://repositorio.unicordoba.edu.co/handle/ucordoba/613210.21897/rmvz.2372https://doi.org/10.21897/rmvz.23721909-0544application/pdfapplication/pdfapplication/zipapplication/zipapplication/xmlapplication/xmlaudio/mpegaudio/mpegspaUniversidad de CórdobaRicardo Rivero-Herrera, Marco González-Tous, Salim Mattar - 2021https://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2https://revistamvz.unicordoba.edu.co/article/view/e2372SARS-CoV-2vaccinesviral strainsSARS-CoV-2vacunascepas viralesVacunas SARS-CoV-2: evolución y escapeSARS-CoV-2 vaccines: evolution and escapeArtículo de revistaJournal articleinfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_b239http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/ARTEDIThttp://purl.org/coar/version/c_970fb48d4fbd8a85Worldometer. COVID-19 coronavirus pandemic. [Internet]. Worldometer; 2021. Available from: https://www.worldometers.info/coronavirus/Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48):eabc8413. https://doi.org/10.1126/sciimmunol.abc8413Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389NIH. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released. USA: National Institutes of Health (NIH); 2021. https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-releasedAstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. Cambridge, UK, AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.htmlLogunov DY, Dolzhikova I V., Shcheblyakov D V., Tukhvatulin AI, Zubkova O V., Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397(10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC - Supply Vaccines to Eliminate Human Diseases. Available from: http://www.sinovac.com/?optionid=754&auto_id=922Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; https://doi.org/10.1038/s41591-021-01285-xCallaway E. The coronavirus is mutating - does it matter? Nature. 2020; 585:174-177. https://doi.org/10.1038/d41586-020-02544-6Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMc2102179Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021. https://doi.org/10.1038/s41586-021-03324-6Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184:1-12. https://doi.org/10.1016/j.cell.2021.03.013van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv. 2020; 11.17.20233726. https://doi.org/10.1101/2020.11.17.20233726Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020; 9: e61312. https://doi.org/10.7554/eLife.61312https://revistamvz.unicordoba.edu.co/article/download/e2372/2982https://revistamvz.unicordoba.edu.co/article/download/e2372/2983https://revistamvz.unicordoba.edu.co/article/download/e2372/3484https://revistamvz.unicordoba.edu.co/article/download/e2372/3486https://revistamvz.unicordoba.edu.co/article/download/e2372/3485https://revistamvz.unicordoba.edu.co/article/download/e2372/3487https://revistamvz.unicordoba.edu.co/article/download/e2372/2984https://revistamvz.unicordoba.edu.co/article/download/e2372/2985Núm. 3 , Año 2021 : Revista MVZ Córdoba Volumen 26(3) Septiembre-Diciembre 2021e23723e237226Revista MVZ CórdobaPublicationOREORE.xmltext/xml3118https://repositorio.unicordoba.edu.co/bitstreams/ff733d9c-2bba-4fdc-8790-827a86e88ecc/downloadf68c58c90f22dc6b08eb02d4e297246fMD51ucordoba/6132oai:repositorio.unicordoba.edu.co:ucordoba/61322023-10-06 00:46:38.197https://creativecommons.org/licenses/by-nc-sa/4.0/Ricardo Rivero-Herrera, Marco González-Tous, Salim Mattar - 2021metadata.onlyhttps://repositorio.unicordoba.edu.coRepositorio Universidad de Córdobabdigital@metabiblioteca.com

Vacunas SARS-CoV-2: evolución y escape

Publicaciones similares